Skip to content

Testing a new blood glucose management software tool for people with type 2 diabetes mellitus

A novel digital glycaemic management tool for people with type 2 diabetes mellitus: a pilot study

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12624000275561
Enrollment
20
Registered
2024-03-18
Start date
2024-03-29
Completion date
2024-06-30
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Our research team has developed a mobile application that tracks dietary intake and blood glucose levels by connecting to a continuous glucose monitor. This study has four study objectives: (1) assess the benefit of this application on participant’s blood glucose, (2) assess the inter-individual and intra-individual variability of post-prandial glucose levels comparing how individuals respond to different foods, and how individuals respond to the same food at different timepoints (intra- and inter-individual variability), (3) assess how accurate the application is at measuring energy intake, and (4) assess how easy the app is to use.

Interventions

This is a single-arm cross-over trial. The intervention is a novel digital glycaemic management tool that allows participants to track their dietary intake using text-based input or automated image-based input. Text-based input involves the participant text-searching a nutritional database. Automated image-based input uses the devices camera and the Passio Nutrition AI tool (Passio Inc., Palo Alto, US) that provides suggested food items based on machine learning recognition of images. The tool a

This is a single-arm cross-over trial. The intervention is a novel digital glycaemic management tool that allows participants to track their dietary intake using text-based input or automated image-based input. Text-based input involves the participant text-searching a nutritional database. Automated image-based input uses the devices camera and the Passio Nutrition AI tool (Passio Inc., Palo Alto, US) that provides suggested food items based on machine learning recognition of images. The tool also integrates with a continuous glucose monitor to display the participant's blood glucose level alongside their dietary intake. This tool is novel and has been developed for this project. Participants will be instructed and educated on how to interpret the blood glucose curve to inform dietary decisions. Access to this tool and continuous glucose monitors will be provided for 20 days. Participants will be educated on the use of the application at the first study visit, prior to recording their dietary intake. Study visit one will take place immediately after the successful screening visit or at a later date, per the participants preference. This will involve how to download the application, creating an application profile, using the text-based input, using the image-based input, using additional application features such as favouriting items and creating custom food items. Study visit 2 takes place at least ten days after study visit 1. At study visit 2 participants will be shown how to connect, use, and interpret the continuous glucose monitor display. The education and instruction at study visit 1 will take approximately 45 minutes, and approximately 20 minutes at study visit 2. Adherence to the tool is assessed through a secondary objective: measured energy intake through the application compared to objectively measured energy expenditure. Adherence is promoted through the use of a novel prompting system that sends reminders to the users via their device notification system based on user-specific metrics; please see the protocol for full details. A secondary objective, measuring the intra-individual and inter-individual variability of post-prandial glycaemic responses, will be assessed by providing participants with a high GI meal and a low GI meal at three points at the study. This is to determine if participants have consistent post-prandial glycaemic reactions to meals, for example, a consistently larger post-prandial glycaemic response to the high GI meal versus the low GI meal, and if the differences between individuals are larger than the variation within individuals. One set of meals, that is, one low GI meal and high GI meal, will be provided at visit one, and two sets provided at visit two. Participants will be instructed to consume the meals within 10 minutes after an overnight fast without any accompanying food items. The low GI meal are wheat flakes, and the high GI meal is corn flakes. Analysis of inter- and intra-individual variation will proceed with analysis run and reported separately for low-GI and high-GI meals (as this is another source of variation in responding). This will use descriptive statistics (per-participant standard deviations of outcomes) and analysis using linear mixed models with a random intercept for each participant. These models will estimate intra-individual variation (akin to an average standard deviation across all participants) and inter-individual variation, with 95% confidence intervals for each. The same analysis will provide an intraclass correlation coefficient (ICC) expressing the relative contribution of intra-individual variation to the overall variation in outcomes.

Sponsors

University of Otago
Lead SponsorUniversity

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• Aged >=18 years • Type 2 diabetes with an HbA1c 65-90 mmol/mol on any hypoglycaemic therapeutic regimen other than insulin. o If the individual has a high baseline time-in-range, the potential improvements will be difficult to detect at smaller sample sizes, which necessitates selecting for those who have the greatest potential for benefit. Participants with an HbA1c >90 mmol/mol should have additional therapy initiated and will therefore be ineligible for this trial. • Speaks and reads English o Due to scope limitations, the application has only been developed in English • Owns an iOS device capable of running iOS 16 and above o These are the technical specifications required to use the application • Able to consume dairy milk and gluten

Exclusion criteria

• Type 1 diabetes or forms of diabetes other than type 2. • Changes to diabetes-related medications or dosing in the last three months • Insulin or intention to initiate insulin therapy during the trial o Although this application may have future benefit to people living with diabetes who require insulin therapy, the use of insulin will make it difficult to assess the isolated effect of dietary change on glycaemic management. • Intention to change dosage of anti-hyperglycaemic agents or initiate continuous glucose monitoring during the trial • Pregnancy • Participation in another trial requiring a prescriptive nutritional intake. o As this study is examining the effect of changing nutritional intake informed by the application, the participant must be able to change their intake at will, which would contradict the trial requiring prescriptive nutritional intake.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026